Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma: results of a multicentre phase II trial
The study indicates that short-term chemotherapy followed by ICI rechallenge can overcome primary ICI resistance in patients with melanoma, supporting its potential as a new therapeutic option in clinical practice.
Authors
- Carola Berking
- Bastian Schilling (ORCID: https://orcid.org/0000-0001-8859-4103)
- Michael Erdmann (ORCID: https://orcid.org/0000-0001-7136-6489)
- Anja Gesierich
- Sebastian Haferkamp (ORCID: https://orcid.org/0000-0002-3894-8345)
- Lea Jakob (ORCID: https://orcid.org/0000-0002-9659-0353)
- Konstantin Drexler (ORCID: https://orcid.org/0009-0004-6601-6299)
- Edward K. Geissler (ORCID: https://orcid.org/0000-0003-3661-6168)
- Florian Zeman (ORCID: https://orcid.org/0000-0002-8425-984X)
- Dirk Tomsitz (ORCID: https://orcid.org/0000-0003-0036-072X)
- Lucie Heinzerling (ORCID: https://orcid.org/0000-0001-5718-3643)
Institutions
- Goethe University Frankfurt (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- LMU Klinikum (DE)
- University Hospital Regensburg (DE)
- Universitätsklinikum Erlangen (DE)
- Universitätsklinikum Würzburg (DE)
- Cancer Research Center (US)
- University Hospital Frankfurt (DE)
- Centro de Investigación del Cáncer (ES)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-09-03
- DOI
- https://doi.org/10.1093/bjd/ljaf350
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Sanofi
- Regeneron Pharmaceuticals
- Les Laboratories Pierre Fabre
- SkylineDx
- Deutsche Krebshilfe
- InflaRx